Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.62 |
| ▸ | PPARA | Q07869 | 2/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.58 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | BCL2 | P10415 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 6/20 | 0.47 |
| ▸ | CTSK | P43235 | 5/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.47 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4797933 | 1.00 | PPARG (0.62) | PPARGPPARAITGB3ITGA2BACE | |
| SCHEMBL440723 | 0.94 | PPARA (0.68) | PPARGPPARAITGB3ITGA2BACE | |
| SCHEMBL199415 | 0.94 | PPARA (0.68) | PPARGPPARAITGB3ITGA2BACE | |
| SCHEMBL441283 | 0.94 | PPARA (0.68) | PPARGPPARAITGB3ITGA2BACE | |
| SCHEMBL13902124 | 0.90 | PPARG (0.53) | PPARGPPARAITGB3ITGA2BBCL2 | |
| SCHEMBL4080957 | 0.90 | PPARG (0.53) | PPARGPPARAITGB3ITGA2BBCL2 | |
| SCHEMBL8218000 | 0.88 | ITGB3 (0.53) | PPARGPPARAITGB3ITGA2BACE | |
| SCHEMBL8976947 | 0.88 | PPARA (0.60) | PPARGPPARAITGB3ITGA2BACE | |
| SCHEMBL3821796 | 0.87 | PPARA (0.60) | PPARGPPARAITGB3ITGA2BACE | |
| SCHEMBL3923929 | 0.86 | ACE (0.65) | PPARGPPARAITGB3ITGA2BACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082408-A1 | NOVEL HETEROCYCLIC DERIVATIVES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2009-03-26 | — | — | US | disclosed |
| WO-2008029217-A2 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082408-A1 | NOVEL HETEROCYCLIC DERIVATIVES | CYP3A5, CYP3A7, UGT2B7 | PPARG 1089/4885PPARA 3465/4885ITGB3 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.